John F. Reinhardt
Christiana Care Health System
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John F. Reinhardt.
The New England Journal of Medicine | 2002
Thomas J. Walsh; Peter G. Pappas; Drew J. Winston; Hillard M. Lazarus; Finn Bo Petersen; John Raffalli; Saul Yanovich; Patrick J. Stiff; Richard N. Greenberg; Gerald R. Donowitz; Mindy G. Schuster; Annette C. Reboli; John R. Wingard; Carola Arndt; John F. Reinhardt; Susan Hadley; Robert W. Finberg; Michél Laverdière; John R. Perfect; Gary Garber; Giuseppe Fioritoni; Eli Anaissie; Jeanette Lee
BACKGROUND Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative. METHODS In a randomized, international, multicenter trial, we compared voriconazole, a new second-generation triazole, with liposomal amphotericin B for empirical antifungal therapy. RESULTS A total of 837 patients (415 assigned to voriconazole and 422 to liposomal amphotericin B) were evaluated for success of treatment. The overall success rates were 26.0 percent with voriconazole and 30.6 percent with liposomal amphotericin B (95 percent confidence interval for the difference, -10.6 to 1.6 percentage points); these rates were independent of the administration of antifungal prophylaxis or the use of colony-stimulating factors. There were fewer documented breakthrough fungal infections in patients treated with voriconazole than in those treated with liposomal amphotericin B (8 [1.9 percent] vs. 21 [5.0 percent], P=0.02). The voriconazole group had fewer cases of severe infusion-related reactions (P<0.01) and of nephrotoxicity (P<0.001). The incidence of hepatotoxicity was similar in the two groups. Patients receiving voriconazole had more episodes of transient visual changes than those receiving liposomal amphotericin B (22 percent vs. 1 percent, P<0.001) and more hallucinations (4.3 percent vs. 0.5 percent, P<0.001). Parenteral voriconazole was changed to the oral formulation in 22 percent of the voriconazole group, with a reduction in the mean duration of hospitalization by one day in all patients (P=0.17) but by two days in patients at high risk (P=0.03). CONCLUSIONS Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever.
Antimicrobial Agents and Chemotherapy | 2004
David Krause; John F. Reinhardt; Jose A. Vazquez; Annette Reboli; Beth P. Goldstein; Michele Wible; Timothy Henkel
ABSTRACT This study evaluated the safety and efficacy of anidulafungin, a novel echinocandin, in patients with invasive candidiasis, including candidemia. A total of 123 eligible patients were randomized to one of three intravenous regimens, 50, 75, or 100 mg once daily. Treatment continued for 2 weeks beyond resolution or improvement of signs and symptoms. The primary efficacy criterion was a successful global response rate (i.e., clinical and microbiological success) in the evaluable population at the follow-up (FU) visit, 2 weeks after end of therapy (EOT). One hundred twenty (120) patients received at least one dose of anidulafungin; 68 were evaluable. Review of adverse events and laboratory data indicated no dose response for safety parameters. Non-albicans Candida species accounted for approximately one-half of all isolates. Success rates at EOT were 84, 90, and 89% in the 50-, 75-, and 100-mg groups, respectively. At FU, the success rates were 72, 85, and 83%. Phase 3 studies of anidulafungin for the treatment of invasive candidiasis and candidemia are warranted.
Antimicrobial Agents and Chemotherapy | 1987
Sydney M. Finegold; L. Ingram-Drake; R. Gee; John F. Reinhardt; M. A. C. Edelstein; K. Macdonald; H. Wexler
Twelve healthy young male subjects received either cefixime, a new oral cephalosporin (CL 284,635), or cefaclor (six subjects on each drug) orally for 2 weeks. In the case of cefixime, single daily doses of 400 mg were taken; with cefaclor, the dosage was 250 mg three times daily. Modest changes in the fecal flora were noted in both drug groups, but the changes were of different types. In the case of cefixime, there was more of an impact on the indigenous flora, and in the case of cefaclor, there was more ingrowth of new flora. With cefixime, Enterobacteriaceae were usually decreased (the decrease in Escherichia coli count was statistically significant), as were counts of clostridia and sometimes Bifidobacterium spp.; the Bacteroides fragilis group was eliminated in one subject. Coincident with these decreases, four subjects had increases in counts of group D streptococci of 3 logs or more. There was new appearance of Clostridium difficile in four subjects and of Staphylococcus aureus in one; four new strains of Enterobacteriaceae appeared. With cefaclor, there was no decrease of E. coli counts; two subjects had elimination of Bifidobacterium spp. There was little change in counts of group D streptococci. On the other hand, there were 13 new strains of Enterobacteriaceae, two of S. aureus, and three of C. difficile.
Annals of Pharmacotherapy | 2015
Jamie M. Rosini; Julie Laughner; Brian J. Levine; Mia A. Papas; John F. Reinhardt; Neil Jasani
Background: Optimizing vancomycin dosing may help eradicate bacteria while avoiding resistance. The guidelines recommend loading doses; however, there are no data to demonstrate that this may result in a more rapid achievement of therapeutic troughs. Objective: To evaluate the percentage of troughs reaching therapeutic levels at 12, 24, and 36 hours following an initial vancomycin dose of 30 mg/kg compared with 15 mg/kg. Methods: This prospective, randomized study was performed in a community academic medical center. Patients who were to receive vancomycin in the emergency department were randomized to an initial traditional dose of 15 mg/kg or a 30-mg/kg loading dose followed by 15 mg/kg every 12 hours for 3 doses. Patients weighing >120 kg or with creatinine clearances <50 mL/min were excluded. Results: In total, 99 patients were enrolled; 12 hours after the initial dose of vancomycin, there was a significantly greater proportion of patients reaching target trough levels of 15 mg/L among the patients who received a loading dose as compared with a traditional dose (34% vs 3%, P < 0.01). This trend continued at 24 hours but was not statistically significant. At 36 hours, there was no difference in the percentage of patients reaching target levels between the 2 groups. No statistically significant difference in nephrotoxicity or adverse events among the 2 groups was demonstrated. Conclusion: A loading dose of 30 mg/kg of vancomycin achieved a higher percentage of therapeutic levels at 12 hours when compared with the traditional dose of 15 mg/kg, without increased nephrotoxicity or adverse events.
BMC Infectious Diseases | 2014
Jose A. Vazquez; Annette C. Reboli; Peter G. Pappas; Thomas F. Patterson; John F. Reinhardt; Peter Chin-Hong; Ellis Tobin; Daniel H. Kett; Pinaki Biswas; Robert Swanson
Clinical Infectious Diseases | 1998
John F. Reinhardt
Clinical Infectious Diseases | 1986
John F. Reinhardt; Lynn Johnston; Peter Ruane; Caroline C. Johnson; Leslie Ingram-drake; Keith MacDonald; Kevin W. Ward; Glenn E. Mathisen; W. Lance George; Sydney M. Finegold; Maury Ellis Mulligan
Clinical Infectious Diseases | 1994
Kenneth S. Babe; John F. Reinhardt
Antimicrobial Agents and Chemotherapy | 2018
G. Ralph Corey; Jeffery S. Loutit; Greg Moeck; Matthew Wikler; Michael N. Dudley; William O'Riordan; Jesús Fortún Abete; Peter Altmeyer; Marc D. Basson; Borys G. Bezrodnyi; Robert O. Brennan; Natalia A. Bubnova; Abhijit Chandra; Ashok Annadan Chandrasekharan; James K. Chen; Constantin Condrea; Maria del Rayo Morfin; Oscar DeValle; Lala M. Dunbar; Dipesh Duttarroy; Philip Giordano; Julian Gonzalez; Miguel Gorgolas; Donald R. Graham; Sinikka Green; Ivan Gudz; Sandeep Kumar Gupta; Barry N. Heller; Osamah Hussein; Luis Jauregui-Peredo
Clinical Infectious Diseases | 1998
Sherwood L. Gorbach; John G. Bartlett; Neil R. Blacklow; John F. Reinhardt